Paloma Partners Management CO Dynavax Technologies Corp Transaction History

Paloma Partners Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $11.61 $252,385 - $291,561	25,113 New	25,113 $279,000
Q4 2020 Feb 16, 2021	SELL	$3.73 - $5.6 $68,777 - $103,258	-18,439 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.32 - $11.7 $79,656 - $215,736	18,439 New	18,439 $80,000
Q1 2019 May 15, 2019	SELL	$7.08 - $12.09 $131,688 - $224,874	-18,600 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $63,052 - $102,866	-7,746 Reduced 29.4%	18,600 $170,000
Q3 2018 Nov 14, 2018	BUY	$11.85 - $16.0 $312,200 - $421,536	26,346 New	26,346 $327,000
Q1 2018 May 15, 2018	SELL	$14.65 - $19.9 $259,729 - $352,807	-17,729 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$17.3 - $24.08 $306,711 - $426,914	17,729	17,729 $331,000

288

131M

507K

374K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.74B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.